Form 13-F position report

IMMUNOGEN INC

Reported by JPMorgan Chase & Co

IMGN CUSIP 45253H101 Manager CIK 0000019617

Reported 2,063,254 shares, down 135,173 (6.1%) from the prior quarter.

Reported value 75.3%; share count -6.1% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q4 2023
Shares 2,063,254 Quarter-end amount reported
Reported value $61,175,480 Fair value at quarter end
Consecutive quarters held 28 Through Q4 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 500000
2021-12-31 709000
2022-03-31 598000
2022-06-30 568000
2022-09-30 638000
2022-12-31 1074000
2023-03-31 3720120
2023-06-30 16273904
2023-09-30 34889037
2023-12-31 61175480
2024-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for IMMUNOGEN INC held by JPMorgan Chase & Co.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2024 Reduced 0 -2,063,254 (-100.0%) 0 $0 2024-05-10
Q4 2023 Reduced 2,063,254 -135,173 (-6.1%) < 0.01% $61,175,480 2024-02-12
Q3 2023 Added 2,198,427 +1,336,005 (154.9%) < 0.01% $34,889,037 2023-11-14
Q2 2023 Reduced 862,422 -106,311 (-11.0%) < 0.01% $16,273,904 2023-08-11
Q1 2023 Added 968,733 +752,266 (347.5%) < 0.01% $3,720,120 2023-05-11
Q4 2022 Added 216,467 +82,963 (62.1%) < 0.01% $1,074,000 2023-02-13
Q3 2022 Added 133,504 +7,452 (5.9%) < 0.01% $638,000 2022-11-14
Q2 2022 Added 126,052 +479 (0.4%) < 0.01% $568,000 2022-08-11
Q1 2022 Added 125,573 +30,112 (31.5%) < 0.01% $598,000 2022-05-11
Q4 2021 Added 95,461 +7,191 (8.1%) < 0.01% $709,000 2022-02-10
Q3 2021 Added 88,270 +1,258 (1.4%) < 0.01% $500,000 2021-11-12
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

399 managers reported IMMUNOGEN INC for Q4 2023.

Managers reporting IMMUNOGEN INC in Q4 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 25,466,950 +984,795 0.02% $755,095,068 43 qtrs
RA CAPITAL MANAGEMENT L P Added 23,750,601 +10,428,313 11.0% $704,205,320 16 qtrs
BlackRock Inc Added 21,824,392 +1,550,533 0.02% $647,093,212 43 qtrs
Redmile Group LLC Reduced 16,423,922 -1,079,495 17.42% $486,969,287 28 qtrs
JANUS HENDERSON GROUP PLC Reduced 11,043,986 -6,640,830 0.2% $327,488,981 10 qtrs
STATE STREET CORPORATION Reduced 8,075,671 -1,476,181 0.01% $239,443,645 43 qtrs
Fairmount Funds Management LLC Unchanged 5,929,592 0 18.58% $175,812,403 3 qtrs
Pentwater Capital Management LP New 5,662,500 +5,662,500 1.88% $167,893,125 1 qtr
NORGES BANK Added 5,539,334 +3,484,245 0.03% $164,241,253 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 5,382,875 +482,900 0.02% $159,620,266 43 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2023
Filed
February 12, 2024
Filing type
13F-HR
Position type
COMMON

Voting authority reported

Sole
1,042,531
Shared
23,856
None
996,867

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.